Psychopharmacologic Treatment for Pediatric Anxiety Disorders

Child and Adolescent Psychiatric Clinics of North America

Volumn 21, Issue 4, 2012, Pages 789-806

  Peters, Todd E ^a   Connolly, Sucheta ^b  

^a Psychiatric Hospital at Vanderbilt   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Anxiety; Children; Psychopharmacology; Review; SSRI

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; DESIPRAMINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LORAZEPAM; MEMANTINE; PAROXETINE; PLACEBO; PROPRANOLOL; PSYCHOTROPIC AGENT; RILUZOLE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADJUVANT THERAPY; AKATHISIA; ANXIETY DISORDER; APATHY; AUDITORY HALLUCINATION; BLUNTED AFFECT; CHILD HEALTH CARE; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; COMORBIDITY; DECREASED APPETITE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSPEPSIA; ENURESIS; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HEADACHE; HOSTILITY; HUMAN; HYPERKINESIA; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; NAUSEA; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; PANIC; PATIENT COMPLIANCE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SEDATION; SEPARATION ANXIETY; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; TIC; TREATMENT DURATION; TREATMENT PLANNING; TREMOR; UNSPECIFIED SIDE EFFECT; VISUAL HALLUCINATION; VOMITING; WITHDRAWAL SYNDROME;

ADOLESCENT; ANXIETY DISORDERS; CHILD; HUMANS; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS;

EID: 84867052289     PISSN: 10564993     EISSN: 15580490     Source Type: Journal    
DOI: 10.1016/j.chc.2012.07.007     Document Type: Review

References (93)

1. Krain A.L., Ghaffari M., Freeman J., et al. Anxiety disorders. Lewis's child and adolescent psychiatry 2007, 538-547. Lippincott, Williams & Wilkins, Philadelphia. A. Martin, F.R. Volkmar (Eds.).
2. Achenbach T.M., Howell C.T., McConaughy S.H., et al. Six-year predictors of problems in a national sample of children and youth: I. Cross-informant syndromes. J Am Acad Child Adolesc Psychiatry 1995, 34:336-347.
3. Gurley D., Cohen P., Pine D.S., et al. Discriminating depression and anxiety in youth: a role for diagnostic criteria. J Affect Disord 1996, 39:191-200.
4. Costello E.J., Mustillo S., Erkanli A., et al. Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry 2003, 60:837-844.
5. Costello E.J., Egger H.L., Angold A. Developmental epidemiology of anxiety disorders. Phobic and anxiety disorders in children and adolescents 2004, 334-380. Oxford University Press, New York. T.H. Ollendick, J.S. March (Eds.).
6. Marmorstein N.R. Generalized versus performance-focused social phobia: patterns of comorbidity among male and female youth. J Anxiety Disord 2006, 20:778-793.
7. Bitner A., Egger H.L., Erkanli A., et al. What do childhood anxiety disorders predict?. J Child Psychol Psychiatry 2007, 48:1174-1183.
8. Connolly S.D., Suarez L., Sylvester C. Assessment and treatment of anxiety disorders in children and adolescents. Curr Psychiatry Rep 2011, 13:99-110.
9. Seligman L.D., Ollendick T.H. Cognitive-behavioral therapy for anxiety disorders in youth. Child Adolesc Psychiatr Clin N Am 2011, 20:217-238.
10. Kircanski K., Peris T.S., Piancentini J.C. Cognitive-behavioral therapy for obsessive-compulsive disorder in children and adolescents. Child Adolesc Psychiatr Clin N Am 2011, 20:239-254.
11. Dorsey S., Briggs E.C., Woods B.A. Cognitive-behavioral treatment for posttraumatic stress disorder in children and adolescents. Child Adolesc Psychiatr Clin N Am 2011, 20:255-270.
12. American Academy of Child and Adolescent Psychiatry Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003, 46:267-283.
13. Walkup J.T., Albano A.M., Piancentini J., et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008, 359:2753-2766.
14. Seidel L., Walkup J.T. Selective serotonin reuptake inhibitor use in the treatment of pediatric non-obsessive-compulsive disorder anxiety disorders. J Child Adolesc Psychopharmacol 2006, 16:171-179.
15. Reinblatt S.P., Riddle M.A. The pharmacological management of childhood anxiety disorders: a review. Psychopharmacology 2007, 191:67-86.
16. Ginsburg G.S., Walkup J.T. Specific phobia. Phobic and anxiety disorders in children and adolescents 2004, 175-197. Oxford University Press, New York. T.H. Ollendick, J.S. March (Eds.).
17. Waslick B. Psychopharmacology interventions for pediatric anxiety disorders: a research update. Child Adolesc Psychiatr Clin N Am 2006, 15:51-71.
18. Viana A.G., Beidel D.C., Rabian B. Selective mutism: a review and integration of the last 15 years. Clin Psychol Rev 2009, 29:57-67.
19. Black B., Uhde T.W. Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1994, 33:1000-1006.
20. Kristensen H. Selective mutism and comorbidity with developmental disorder/delay, anxiety disorder, and elimination disorder. J Am Acad Child Adolesc Psychiatry 2000, 39:249-256.
21. Lepola U., Leinonen E., Koponen H. Citalopram in the treatment of early-onset panic disorder and school phobia. Pharmacopsychiatry 1996, 29:30-32.
22. Mancini C., Van Ameringen M., Oakman J.M., et al. Serotonergic agents in the treatment of social phobia in children and adolescents: a case series. Depress Anxiety 1999, 10:33-39.
23. Birmaher B., Waterman G.S., Ryan N., et al. Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 1994, 33:993-999.
24. Fairbanks J.M., Pine D.S., Tancer N.K., et al. Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. J Child Adolesc Psychopharmacol 1997, 7:17-29.
25. Compton S.N., Grant P.J., Chrisman A.K., et al. Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry 2001, 40:564-571.
26. Research Unit on Pediatric Psychopharmacology Anxiety Disorders Study Group Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med 2001, 344:1279-1285.
27. Rynn M.A., Siqueland L., Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001, 158:2008-2014.
28. Birmaher B., Axelson D.A., Monk K., et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003, 42:415-423.
29. Wagner K.D., Berard R., Stein M.B., et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 2004, 61:1153-1162.
30. Beidel D.C., Turner S.M., Sallee F.R., et al. SET-C versus fluoxetine in the treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry 2007, 46:1622-1632.
31. Compton S.N., Walkup J.T., Albano A.M., et al. Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods. Child Adolesc Psychiatry Ment Health 2010, 4:1.
32. Ginsburg G.S., Kendall P.C., Sakolsky D., et al. Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol 2011, 79:806-813.
33. March J.S., Entusah A.R., Rynn M. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry 2007, 62:1149-1154.
34. Rynn M.A., Riddle M.A., Yeung P.P., et al. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry 2007, 164:290-300.
35. Gittelman-Klein R., Klein D.F. Controlled imipramine treatment of school phobia. Arch Gen Psychiatry 1971, 25:204-207.
36. Berney T., Kolvin I., Bhate S.R., et al. School phobia: a therapeutic trial with clomipramine and short-term outcome. Br J Psychiatry 1981, 138:110-118.
37. Klein R.G., Koplewicz H.S., Kanner A. Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry 1992, 31:21-28.
38. Bernstein G.A., Borchardt C.M., Perwein A.R., et al. Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry 2000, 39:276-283.
39. Bernstein G.A., Hektner J.M., Borchardt C.M., et al. Treatment of school refusal: one-year follow-up. J Am Acad Child Adolesc Psychiatry 2001, 40:206-213.
40. Layne A.E., Bernstein G.A., Egan E.A., et al. Predictors of treatment response in anxious-depressed adolescents with school refusal. J Am Acad Child Adolesc Psychiatry 2003, 42:319-326.
41. Bernstein G.A., Garfinkel B.D., Borshardt C.M. Comparative studies of pharmacotherapy for school refusal. J Am Acad Child Adolesc Psychiatry 1990, 29:773-781.
42. Simeon J.G., Ferguson H.B., Knott V., et al. Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry 1992, 31:29-33.
43. Graae F., Milner J., Rizzotto L., et al. Clonazepam in childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 1994, 33:372-376.
44. Renaud J., Birhamer B., Wassick S.C., et al. Use of selective serotonin reuptake inhibitors for the treatment of childhood panic disorder: a pilot study. J Child Adolesc Psychopharmacol 1999, 9:73-83.
45. Simeon J.G. Use of anxiolytics in children. Encephale 1993, 19:71-74.
46. Salazar D.E., Frackiewicz E.J., Dockens R., et al. Pharmacokinetics and tolerability of buspirone during oral administration to children and adolescents with anxiety disorder and normal healthy adults. J Clin Pharmacol 2001, 41:1351-1358.
47. Masi G., Toni C., Mucci M., et al. Paroxetine in child and adolescent outpatients with panic disorder. J Child Adolesc Psychopharmacol 2001, 11:151-157.
48. Fisman S.N. Pharmacological treatment of major depressive disorder in children and adolescents: the paroxetine controversy. Can J Clin Pharmacol 2004, 11:e214-e217.
49. Nestadt G., Samuels J., Bienvenu J.O., et al. A family study of obsessive compulsive disorder. Arch Gen Psychiatry 2000, 57:358-363.
50. American Academy of Child and Adolescent Psychiatry Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2012, 51:98-113.
51. Swedo S.E., Leonard H.L., Garvey M., et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998, 155:264-271.
52. Swedo S.E., Leonard H.L., Rapoport J.L. The Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infection (PANDAS) subgroup: separating fact from fiction. Pediatrics 2004, 113:907-911.
53. Leslie D.L., Kozma L., Martin A., et al. Neuropsychiatric disorders associated with streptococcal infection: a case-control study among privately insured children. J Am Acad Child Adolesc Psychiatry 2008, 47:1166-1172.
54. Kurlan R., Johnson D., Laplan E.L., Tourette Syndrome Study Group Streptococcal infection and exacerbations of childhood tics and obsessive-compulsive symptoms: a prospective blinded cohort study. Pediatrics 2008, 121:1188-1197.
55. Leckman J.F., King R.A., Gilbert D.L., et al. Streptococcal upper respiratory tract infections and exacerbations of tic and obsessive-compulsive symptoms: a prospective longitudinal study. J Am Acad Child Adolesc Psychiatry 2011, 50:108-118.
56. Storch E.A., Merlo L.J., Larson M.J., et al. Impact of comorbidity on cognitive-behavioral therapy response in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2008, 47:583-592.
57. Franklin M.E., Sapyta J., Freeman J.B., et al. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. JAMA 2011, 306(11):1224-1232.
58. Leonard H.L., Swedo S.E., Rapoport J.L., et al. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison. Arch Gen Psychiatry 1989, 46:1088-1092.
59. DeVeaugh-Geiss J., Moroz G., Biederman J., et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder-a multicenter trial. J Am Acad Child Adolesc Psychiatry 1992, 31:45-49.
60. Leonard H.L., Swedo S.E., Lenane M.C., et al. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1991, 48:922-927.
61. March J.S., Biederman J., Wolkow R., et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 1998, 280:1752-1756.
62. Riddle M.A., Scahill L., King R.A., et al. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992, 31:1062-1069.
63. Geller D.A., Hoog S.L., Heiligenstein J.H., et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 2001, 40:773-779.
64. Liebowitz M.R., Turner S.M., Piacentini J., et al. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2002, 41:1431-1438.
65. Riddle M.A., Reeve E.A., Yaryura-Tobias J.A., et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001, 40:222-229.
66. Geller D.A., Wagner K.D., Emslie G., et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2004, 43:1387-1396.
67. Geller D.A., Biederman J., Stewart S.E., et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry 2003, 160:1919-1928. [see comment].
68. Franklin M., Foa E., March J.S. The pediatric obsessive-compulsive disorder treatment study: rationale, design, and methods. J Child Adolesc Psychopharmacol 2003, 13(Suppl 1):S39-S51.
69. Pediatric OCD Treatment Study (POTS) Team Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 2004, 292:1969-1976.
70. Leonard H.L., Topol D., Bukstein O., et al. Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1994, 33:792-794.
71. Costello E.J., Erkanli A., Fairbank J.A., et al. The prevalence of potentially traumatic events in childhood and adolescence. J Trauma Stress 2002, 15:99-112.
72. American Academy of Child and Adolescent Psychiatry Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder. J Am Acad Child Adolesc Psychiatry 2010, 49:414-430.
73. Breslau N., Davis G.C., Andreski P., et al. Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry 1991, 48:216-222.
74. Carrion V.G., Weems C.F., Ray R., et al. Toward an empirical definition of pediatric PTSD: the phenomenology of PTSD in youth. J Am Acad Child Adolesc Psychiatry 2002, 41:166-173.
75. Seedat S., Lockhat R., Kaminer D., et al. An open trial of citalopram in adolescents with post-traumatic stress disorder. Int Clin Psychopharmacol 2001, 16:21-25.
76. Seedat S., Stein D.J., Ziervogel C., et al. Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder. J Child Adolesc Psychopharmacol 2002, 12:37-46.
77. Yorbik O., Dikkatli S., Cansever A., et al. Klin Psikofarmakol Bulteni 2001, 11:251-256. [in Turkish].
78. Robb A.S., Cueva J.E., Sporn J., et al. Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 2010, 20:463-471.
79. Cohen J.A., Mannarino A.P., Perel J.M., et al. A pilot randomized trial of combined trauma-focused CBT and sertraline for childhood PTSD symptoms. J Am Acad Child Adolesc Psychiatry 2007, 46:811-819.
80. Perry B.D. Neurobiological sequelae of childhood trauma: PTSD in children. Catecholamine function in posttraumatic stress disorder: emerging concepts 1994, 223-255. American Psychiatric Press, Washington, DC. M.M. Murburg (Ed.).
81. Harmon R.J., Riggs P.D. Clinical perspectives: clonidine for posttraumatic stress disorder in preschool children. J Am Acad Child Adolesc Psychiatry 1996, 35:1247-1249.
82. De Bellis M.D., Keshevan M.S., Harenski K.A. Case study: anterior cingulate N-acetylaspartate/creatine ratios during clonidine treatment in a maltreated child with posttraumatic stress disorder. J Child Adolesc Psychopharmacol 2001, 11:311-316.
83. Famularo R., Kinscherff R., Fenton T. Propranolol treatment for childhood posttraumatic stress disorder, acute type: a pilot study. Am J Dis Child 1988, 142:1206-1219.
84. Horrigan J.P., Barnhill L.J. Risperidone and PTSD in boys. J Neuropsychiatry Clin Neurosci 1999, 11:126-127.
85. Murphy T.K., Segarra A., Storch E.A., et al. SSRI adverse events: how to monitor and manage. Int Rev Psychiatry 2008, 20:203-208.
86. Bridge J.A., Iyengar S., Salary C.B., et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007, 297:1683-1696.
87. Labellarte M., Biederman J., Emslie G., et al. Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents. J Am Acad Child Adolesc Psychiatry 2004, 43:1497-1505.
88. Gleason M.M., Egger H.L., Emslie G.J., et al. Psychopharmacological treatment for very young children: contexts and guidelines. J Am Acad Child Adolesc Psychiatry 2007, 46:1532-1572.
89. Massanari M., Novitsky J., Reinstein L.J. Paradoxical reactions in children associated with midazolam during endoscopy. Clin Pediatr 1997, 36:681-684.
90. Ista E., van Dijk M., Gamel C., et al. Withdrawal symptoms in children after long-term administration of sedatives and/or analgesics: a literature review: assessment remains troublesome. Intensive Care Med 2007, 33:1396-1406.
91. Birchley G. Opioid and benzodiazepine withdrawal syndromes in the pediatric intensive care unit: a review of recent literature. Nurs Crit Care 2009, 14:26-37.
92. Yeh H.H., Chen C.Y., Fang S.Y., et al. Five-year trajectories of long-term benzodiazepine use by adolescents: patient, provider, and medication factors. Psychiatr Serv 2011, 62:900-907.
93. Pine D.S. Treating children and adolescents with selective serotonin reuptake inhibitors: how long is appropriate?. J Child Adolesc Psychopharmacol 2002, 12:189-203.